Addex Therapeutics (ADXN) said Thursday it has regained full ownership of its experimental epilepsy treatment after Johnson & Johnson (JNJ) owned J&J Innovative Medicine ended their collaboration.
The asset was returned following J&J Innovative Medicine's prior decision to halt further development, the company said.
Addex said the drug, which targets the mGlu2 receptor, has already undergone three mid-stage trials and comes with a comprehensive dataset for future clinical planning.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.